ANABIOTICASubmit a source
Research

Young-Donor Plasma

An unapproved anti-aging intervention extrapolated from animal parabiosis, with no demonstrated clinical benefit and real transfusion-related risks.

Insufficient
Evidence rating
Evidence review

What the evidence says

Young-donor plasma is based partly on heterochronic-parabiosis experiments in which old and young animals share circulation. A plasma transfusion is not parabiosis, and neither animal model identifies a clinically validated rejuvenating product, dose, or schedule for humans.[1][3]

The PLASMA study tested four weekly infusions from young donors in 18 people with mild-to-moderate Alzheimer disease. It primarily supported short-term feasibility; its size and design could not establish cognitive efficacy, and it does not support use in healthy people.[2]

Small trials of GRF6019, a processed plasma-derived fraction, reported acceptable short-term tolerability and exploratory outcome patterns in Alzheimer disease. These products are not young-donor plasma, and uncontrolled or small randomized signals are insufficient for efficacy or general anti-aging claims.[4][5]

Other research tests therapeutic plasma exchange or plasma dilution, which removes and replaces a patient's plasma rather than adding purported youth factors. A 2025 randomized trial may motivate larger studies, but it cannot be used as evidence that commercial young-plasma transfusions work.[3][6]

The FDA states that young-donor plasma has no proven clinical benefit for aging, memory loss, dementia, or other marketed uses and warns of allergic reactions, transfusion-associated circulatory overload, acute lung injury, infection, and other harms. Paying for an unapproved infusion also risks delaying appropriate diagnosis and care.[1]

Potential benefits

  • No anti-aging, cognitive, functional, or longevity benefit has been established for young-donor plasma in humans.[1][2]
  • Early studies help define feasibility and guide better-controlled research on distinct plasma biology approaches.[5][6]

Side effects and cautions

  • Transfusion can cause allergic reactions, circulatory overload, acute lung injury, infection, and other serious complications.[1]
  • Repeated commercial treatment adds vascular-access, donor-exposure, cost, and opportunity harms without proven benefit.[1]
How we scored it

Evidence breakdown

Tiny early human studies and related plasma-fraction or exchange trials cannot establish rejuvenation, while the FDA explicitly warns consumers against commercial young-plasma infusions.

Clinical relevanceLow

Human studies are tiny, often uncontrolled or test related but materially different plasma interventions.

Study qualityLow

No adequately powered randomized trial demonstrates anti-aging benefit from young-donor plasma itself.

Safety dataModerate

General transfusion risks are known, but repeated off-label exposure in healthy customers is not adequately studied.

References

Full source list

  1. Important Information About Young Donor Plasma Infusions Offered for Profit

    U.S. Food and Drug Administration · 2019

  2. Safety, tolerability, and feasibility of young plasma infusion in the Plasma for Alzheimer Symptom Amelioration study

    JAMA Neurology · 2019

  3. Old plasma dilution reduces human biological age: a clinical study

    GeroScience · 2022

  4. A phase II trial of the plasma fraction GRF6019 in severe Alzheimer disease

    Alzheimer's Research & Therapy · 2021

  5. A phase II trial of GRF6019 in mild-to-moderate Alzheimer disease

    Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2020

  6. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange

    Aging Cell · 2025